Pulmonary pharmacology of WAY-126299A: a dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist.
Wyeth-Ayerst Research, Princeton, NJ 08543-8000, USA.
R E
RE
Howell
L P
LP
Jenkins
D A
DA
Hartman
W B
WB
Gray
D
D
Kubrak
R P
RP
Carlson
A F
AF
Kreft
D
D
Grimes
D000081:Acetamides / Q000494:pharmacology*; D000758:Anesthesia; D000818:Animals; D052160:Benzothiazoles; D016084:Bronchoconstriction / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology; D066298:In Vitro Techniques; D017998:Leukotriene D4 / Q000037:antagonists & inhibitors*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D008168:Lung / Q000187:drug effects*; D009280:Naphthaleneacetic Acids / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D012121:Respiration, Artificial; D013844:Thiazoles / Q000494:pharmacology*
D000081:Acetamides; D052160:Benzothiazoles; D016859:Lipoxygenase Inhibitors; D009280:Naphthaleneacetic Acids; D011804:Quinolines; D013844:Thiazoles; C097665:WAY 126299A; C067525:S(alpha)-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid; D017998:Leukotriene D4; C063449:zileuton; D006918:Hydroxyurea